Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Applied BioCodeTPE:6598 -4.23%75 Net Current Asset Value is NT$4.76 as of Dec. 2025, which is 100% below its 10-year median of 4.95. GuruFocus rates TPE:6598 with a GF Score™ of 75/100 and a GF Value™ of NT$23.34 (Fairly Valued). The stock has 6 warning signs investors should review. Among 569 Medical Devices & Instruments companies, Applied BioCode ranks worse than 51.67% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Applied BioCode's net current asset value per share for the quarter that ended in Dec. 2025 was NT$4.76.
The historical rank and industry rank for Applied BioCode's Net Current Asset Value or its related term are showing as below:
TPE:6598'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.7 Med: 4.95 Max: 9.16
Current: 5
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Applied BioCode was 9.16. The lowest was 2.70. And the median was 4.95.
TPE:6598's Price-to-Net-Current-Asset-Value is ranked worse than 51.67% of 569
companies
in the Medical Devices & Instruments industry
Industry Median: 4.91
vs TPE:6598: 5.00
Applied BioCode (TPE:6598) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Applied BioCode Net Current Asset Value Related Terms
Applied BioCode Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Applied BioCode's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6598 vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, Applied BioCode's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Applied BioCode Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Applied BioCode's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Applied BioCode's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of NT$4.76 mean?
Applied BioCode (TPE:6598) has a Net Current Asset Value of NT$4.76 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Applied BioCode and its competitors. This is near median its historical median of 4.95. Over the past decade, Applied BioCode's Net Current Asset Value has ranged from 2.70 to 9.16. According to the industry distribution chart, Applied BioCode ranks #294 out of 569 companies in the Medical Devices & Instruments industry, placing it in the top 51.7%.
Is Applied BioCode's Net Current Asset Value too high?
Applied BioCode's current Net Current Asset Value of NT$4.76 is near median its 10-year median of 4.95. Over the past 10 years, this metric has ranged from a low of 2.70 to a high of 9.16. Based on the distribution chart, Applied BioCode ranks #294 out of 569 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Applied BioCode has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Applied BioCode's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Applied BioCode ranks #294 out of 569 companies for Net Current Asset Value. This places Applied BioCode in the lower half of its industry. The industry median Net Current Asset Value is 4.91. Historically, Applied BioCode's own Net Current Asset Value has ranged from 2.70 to 9.16 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 4.91, based on 569 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Applied BioCode and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 4.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Applied BioCode's current Net Current Asset Value is NT$4.76, which is near median its own 10-year median of 4.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Applied BioCode stock overvalued right now?
Based on GuruFocus' analysis, Applied BioCode (TPE:6598) is currently considered Fairly Valued. The stock's GF Value™ is NT$23.34, compared to a current price of NT$23.80 — trading 2% above its estimated fair value. The current Net Current Asset Value is NT$4.76, which is near median its 10-year median of 4.95. Applied BioCode's overall GF Score™ is 75/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Applied BioCode (TPE:6598), the current Net Current Asset Value is NT$4.76 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Applied BioCode (TPE:6598) Overvalued in 2026?
Based on GuruFocus' analysis, Applied BioCode stock appears to be overvalued.
The current stock price of NT$23.80 is trading 2% above its estimated GF Value™ of NT$23.34.
GuruFocus considers Applied BioCode to be Fairly Valued.
Key valuation signals for TPE:6598:
Net Current Asset Value: NT$4.76 (near median its 10-year median of 4.95)
GF Value™: NT$23.34 vs. price of NT$23.80 (2% above fair value)
No single metric tells the full story. See the TPE:6598 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Applied BioCode Corp is engaged in designing, developing, manufacturing, and commercializing multiplex testing products for the in-vitro diagnostics market. The company's in-vitro diagnostic products focus on the molecular infectious disease segment of the market with assays that detect pathogens for gastrointestinal tract infections, respiratory infections, and sexually transmitted infections. The firm's products include barcoded magnetic bead technology (BMB). The BMB technology and detection systems assist in the development of multiplexed nucleic acids or protein detection assays. The company also develops applications for other areas of the diagnostics industry including life science research, agricultural testing, and veterinary markets.
75GF Score
Get the complete analysis for TPE:6598
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6598 has been successfully added to your 
